Program Director/Principal Investigator (Last, First, Middle): Gau, Vincent Project summary and abstract Standard culture-based diagnosis of bacterial infections, including pathogen identification (ID) and antimicrobial susceptibility testing (AST), require 2-3 days for clinical sample acquisition to result reporting. The absence of definitive microbiological diagnosis at the point of care has largely driven the over- and misuse of antibiotics. While microbiological diagnosis has improved with the availability of high throughput, automated instruments in the larger clinical microbiology laboratories, the process remains time-consuming and requires significant technical expertise. Standard automation instruments are bulky and typically require a priori isolation of the pathogens from the body fluid samples prior to AST . The significant work burden of a modern clinical microbiology laboratory has led increasingly to the practice of outsourcing of clinical laboratory tests. Development of a point-of-care platform capable of rapid pathogen ID and AST can provide clinicians with evidenced-based information to start patient-specific antimicrobial treatment only when necessary. Even short- term alterations in the use of antibiotics have been found to favorably impact the antibiotic resistance profiles. Furthermore, such platform may be useful to expedite screening of novel class of antibiotics. In this proposal, we will leverage our ongoing efforts to develop an integrated diagnostic biochip for rapid pathogen identification (U01 AI082457) by developing a complementary rapid antimicrobial susceptibility testing (RAST) biochip. This proposed study will utilize high aspect ratio, gas permeable microchannels to obtain optimal conditions for rapid phenotypic assessment of bacterial growth and electrokinetic (EK) sample preparation techniques for on chip matrix management, and develop an electrochemical-based RAST fluidic cartridge to obtain antimicrobial susceptibility assessment from confirmed positive patient populations in 90 minutes. The ultimate goal of the AST development is to leverage the advancement of the established microfluidic cartridge technology and the phenotypic assays developed among all key personnel in the assembled team to establish a comprehensive understanding of not only just the urine specimen but also other body fluids. The overall focus of Aim 1 is to characterize the physical properties of the specimen matrix with various impedance analyses and provide a controllable approach to minimize the matrix effect with electrokinetic trapping. By assessing the impedance mapping of each specimen to be tested, a customized electrokinetic sample preparation will be applied to obtain the maximum extraction efficiency instead of using a universal condition for a wide range of specimen conditions. The outcome of the proposed Aim 1 will provide comprehensive impedance mapping of 98% of urine specimens with impedance analysis and this information will be linked to the optimal EK manipulation conditions to be developed in Aim 1. The passing criteria of Specific Aim 2 is to achieve 100% agreement comparing to urine culture with the microfluidic cartridge and associated control system in 90 minutes compared to urine culture. PHS 398/2590 (Rev. 11/07) Page 1 Continuation Format Page

Public Health Relevance

The absence of definitive microbiological diagnosis at the point of care has led to over- and misuse of antibiotics. We propose to develop a biochip-based rapid AST by utilizing high aspect ratio, gas permeable microchannels for rapid phenotypic assessment of bacterial growth, electrokinetic (EK) sample preparation techniques for on chip matrix management, and develop an electrochemical-based RAST fluidic cartridge to obtain antimicrobial susceptibility assessment from infected urine samples in 90 minutes. PHS 398/2590 (Rev. 11/07) Page 1 Continuation Format Page

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
5R43AI088756-02
Application #
8041057
Study Section
Special Emphasis Panel (ZRG1-IDM-P (12))
Program Officer
Ritchie, Alec
Project Start
2010-03-15
Project End
2012-02-29
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
2
Fiscal Year
2011
Total Cost
$358,327
Indirect Cost
Name
Genefluidics, Inc.
Department
Type
DUNS #
122561686
City
Irwindale
State
CA
Country
United States
Zip Code
91010
Sin, Mandy L Y; Liu, Tingting; Pyne, Jeffrey D et al. (2012) In situ electrokinetic enhancement for self-assembled-monolayer-based electrochemical biosensing. Anal Chem 84:2702-7
Gao, Jian; Sin, Mandy L Y; Liu, Tingting et al. (2011) Hybrid electrokinetic manipulation in high-conductivity media. Lab Chip 11:1770-5
Riahi, Reza; Mach, Kathleen E; Mohan, Ruchika et al. (2011) Molecular detection of bacterial pathogens using microparticle enhanced double-stranded DNA probes. Anal Chem 83:6349-54
Mach, Kathleen E; Mohan, Ruchika; Baron, Ellen Jo et al. (2011) A biosensor platform for rapid antimicrobial susceptibility testing directly from clinical samples. J Urol 185:148-53
Sin, Mandy L Y; Gau, Vincent; Liao, Joseph C et al. (2010) Electrothermal Fluid Manipulation of High-Conductivity Samples for Laboratory Automation Applications. JALA Charlottesv Va 15:426-432
Chen, Hsiang Chia; Chen, Chia Hsiang; Gau, Vincent et al. (2010) Statistical metamodeling for revealing synergistic antimicrobial interactions. PLoS One 5:e15472
Chen, Chia Hsiang; Lu, Yi; Sin, Mandy L Y et al. (2010) Antimicrobial susceptibility testing using high surface-to-volume ratio microchannels. Anal Chem 82:1012-9